Cardiac Risk Substantially Lower with Enzalutamide Than Abiraterone

Using the world’s largest pharmacovigilance database, Eugene B. Cone, MD, Quoc-Dien Trinh, MD, and colleagues determined the risk of cardiac adverse events is increased substantially with abiraterone and not at all with enzalutamide.
Read More...